This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Nuvo Pharmaceuticals マネジメント

マネジメント基準チェック /44

主要情報

Jesse Ledger

最高経営責任者

CA$753.5k

報酬総額

CEO給与比率	49.7%
CEO在任期間	6.3yrs
CEOの所有権	1.1%
経営陣の平均在職期間	6.3yrs
取締役会の平均在任期間	17.5yrs

経営陣の近況

Recent updates

CEO報酬分析

Nuvo Pharmaceuticals の収益と比較して、Jesse Ledger の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2022	n/a	n/a	CA$15m
Jun 30 2022	n/a	n/a	-CA$3m
Mar 31 2022	n/a	n/a	-CA$12m
Dec 31 2021	CA$754k	CA$375k	-CA$32m
Sep 30 2021	n/a	n/a	-CA$24m
Jun 30 2021	n/a	n/a	-CA$9m
Mar 31 2021	n/a	n/a	-CA$20m
Dec 31 2020	CA$577k	CA$369k	-CA$4m
Sep 30 2020	n/a	n/a	-CA$7m
Jun 30 2020	n/a	n/a	CA$311k
Mar 31 2020	n/a	n/a	CA$9m
Dec 31 2019	CA$715k	CA$350k	CA$3m
Sep 30 2019	n/a	n/a	-CA$814k
Jun 30 2019	n/a	n/a	-CA$8m
Mar 31 2019	n/a	n/a	-CA$13m
Dec 31 2018	CA$546k	CA$350k	-CA$6m
Sep 30 2018	n/a	n/a	-CA$2m
Jun 30 2018	n/a	n/a	CA$473k
Mar 31 2018	n/a	n/a	-CA$784k
Dec 31 2017	CA$621k	CA$292k	CA$2m
Sep 30 2017	n/a	n/a	CA$4m
Jun 30 2017	n/a	n/a	CA$5m
Mar 31 2017	n/a	n/a	CA$8m
Dec 31 2016	CA$300k	CA$170k	CA$7m

報酬と市場: Jesseの総報酬 ($USD 549.24K ) は、 German市場 ($USD 474.43K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jesseの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jesse Ledger

6.3yrs

在職期間

CA$753,546

報酬

Mr. Jesse F. Ledger has been the Chief Executive Officer of Nuvo Pharmaceuticals Inc. since November 21, 2017 and as its President since November 15, 2016. Mr. Ledger served as Vice President of Business D...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jesse Ledger	President & CEO	6.3yrs	CA$753.55k	1.09% € 114.7k
Mary-Jane Burkett	VP & CFO	6.5yrs	CA$394.05k	0.14% € 15.0k
Bernard Chiasson	VP of Operations & Chief Scientific Officer	5.5yrs	CA$508.45k	0.098% € 10.3k
Katina Loucaides	VP, Corporate Secretary & General Counsel	no data	CA$509.20k	0.20% € 21.4k
Luigi Berardelli	Vice President of Sales & Marketing	no data	CA$448.72k	データなし

6.3yrs

平均在職期間

経験豊富な経営陣: 23Nの経営陣は経験豊富で経験豊富です（平均在職期間は6.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Anthony Dobranowski	Independent Lead Director	18.5yrs	CA$66.75k	0.61% € 64.9k
Rolf Zinkernagel	Member of Scientific Advisory Board	17.5yrs	データなし	データなし
Stefan Meuer	Member of Scientific Advisory Board	17.5yrs	データなし	データなし
Lee Simon	Member of Scientific Advisory Board	17.5yrs	データなし	データなし
John London	Non-Executive Vice-Chairman	18.5yrs	CA$58.75k	1.37% € 144.4k
Daniel Chicoine	Independent Director	18.5yrs	CA$60.75k	2.07% € 218.6k
Mary Ritchie	Independent Director	1.8yrs	CA$36.86k	データなし
Jonathan Wilkin	Member of Scientific Advisory Board	no data	データなし	データなし
Dale Weil	Independent Director	less than a year	データなし	データなし
Robert Harris	Non-Executive Chairman	5.8yrs	CA$93.33k	0.66% € 69.5k
Anthony Snow	Director	less than a year	データなし	データなし

17.5yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: 23Nの取締役会は経験豊富で経験豊富です ( 17.5年の平均在任期間)。

This company listing is no longer active

Nuvo Pharmaceuticals マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Nuvo Pharmaceuticals Inc. Appoints Anthony Snow to the Board of Directors

Nuvo Pharmaceuticals Inc. Appoints Anthony Snow to the Board of Directors

Miravo Healthcare™ Announces Appointment of Dale MacCandlish Weil to Its Board of Directors

Nuvo Pharmaceuticals Inc., Annual General Meeting, May 16, 2022

Nuvo Pharmaceuticals Inc., Annual General Meeting, May 17, 2021

Recent updates

Third quarter 2022 earnings released: EPS: CA$0.039 (vs CA$1.56 loss in 3Q 2021)

Nuvo Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 14, 2022

Nuvo Pharmaceuticals Inc. Appoints Anthony Snow to the Board of Directors

Second quarter 2022 earnings released: EPS: CA$1.61 (vs CA$0.80 in 2Q 2021)

Nuvo Pharmaceuticals Inc. Appoints Anthony Snow to the Board of Directors

Nuvo Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 15, 2022

Miravo Healthcare™ Announces Appointment of Dale MacCandlish Weil to Its Board of Directors

First quarter 2022 earnings released: EPS: CA$0.18 (vs CA$1.58 loss in 1Q 2021)

Nuvo Pharmaceuticals Inc. Provides an Update on the United States Pennsaid® 2% Business

Nuvo Pharmaceuticals Inc. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings released: CA$2.83 loss per share (vs CA$0.36 loss in FY 2020)

Nuvo Pharmaceuticals Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2021

Nuvo Pharmaceuticals Inc., Annual General Meeting, May 16, 2022

Nuvo Pharmaceuticals Inc. Announces Summary Judgment Ruling by the United States District Court for the District of New Jersey

Third quarter 2021 earnings released: CA$1.56 loss per share (vs CA$0.25 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CA$0.80 (vs CA$0.17 loss in 2Q 2020)

First quarter 2021 earnings released: CA$1.58 loss per share (vs CA$0.15 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.36 loss per share (vs CA$0.29 profit in FY 2019)

Revenue beats expectations

Miravo Healthcaretm Ireland Enters into Resultz® License and Supply Agreement with the Mentholatum Company for the United States

Nuvo Pharmaceuticals Inc., Annual General Meeting, May 17, 2021

Nuvo Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 08, 2021

New 90-day high: €0.92

Miravo Healthcare Announces the Canadian Commercial Launch of NeoVisc®+ and NeoVisc® ONE for the Treatment of Pain and Improvement of Joint Functionality of the Knee

New 90-day high: €0.62

Revenue beats expectations

Third quarter 2020 earnings released: CA$0.25 loss per share

Nuvo Pharmaceuticals Inc. to Report Q3, 2020 Results on Nov 16, 2020

New 90-day high: €0.61

Nuvo Pharmaceuticals Inc. (TSX:NRI) completed the acquisition of Aralez Pharmaceuticals Canada Inc. from Aralez Pharmaceuticals Inc. (TSX:ARZ).

New 90-day high: €0.54

New 90-day low - €0.43

Nuvo Pharmaceuticals Inc. to Report Q2, 2020 Results on Aug 10, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44